Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04389866 · ClinicalTrials.gov registry record · NA

Jowl Improvement With Injectable Fillers

A NA study, sponsored by Advanced Dermatology.

Completed
Registry status
NA
Development phase
16
Enrollment target

NCT04389866: Completed NA study, sponsored by Advanced Dermatology.

NCT04389866 is a NA study that has completed, run by Advanced Dermatology. The registered enrollment target is 16 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04389866, a NA study, has completed, sponsored by Advanced Dermatology.

COMPLETED
Registry status
NA
Development phase
16 participants
Enrollment target

Study Summary

This is a prospective clinical study to demonstrate a reduction in jowling and laxity of the jawline that can be achieved following facial volume enhancement using JUVÉDERM VOLUMA™ XC (0.3% w/w lidocaine). The secondary measure will be if this can be achieved with Jawline injection only, or if a superior result can be obtained with both cheek and jowl injection.

Primary Outcome

The primary outcome is a reduction of 1 or more points of the Jawline Rating Scale (JRS) Assessment (on a scale of 0 to 4) at baseline versus that at 4 weeks from the last injection (whether initial or touch-up) based on one blinded dermatologist rating. (A lower number will mean a better outcome) All subject data in respective groups were averaged into a single value at each time point. To clarify the Time Point "4 Weeks from last injection" it means 8 to 12 weeks after baseline as subjects we

Interventions

  • DEVICE JUVÉDERM VOLUMA™ XC

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2020-09-25
Est. Completion 2022-10-05
Phase NA
Advanced Dermatology

2 total trials

What the finished NCT04389866 record still lists

NCT04389866 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 1 intervention - of which JUVÉDERM VOLUMA™ XC is the first listed.

NCT04389866 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04389866 about?

NCT04389866 is a clinical study titled "Jowl Improvement With Injectable Fillers". This is a prospective clinical study to demonstrate a reduction in jowling and laxity of the jawline that can be achieved following facial volume enhancement using JUVÉDERM VOLUMA™ XC (0.3% w/w lidocaine). The secondary measure will be if this can be achieved with Jawline injection only, or if a sup...

What is the current status of trial NCT04389866?

This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2020-09-25. Estimated completion is 2022-10-05.

What interventions are being tested in trial NCT04389866?

The interventions under investigation include: JUVÉDERM VOLUMA™ XC (DEVICE).

Who is sponsoring clinical trial NCT04389866?

This trial is sponsored by Advanced Dermatology, which has 2 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04389866's enrollment target sits among peer trials

16 1871st of 2000 higher than 120 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04389866, the US trial registry maintained by the National Library of Medicine. NCT04389866 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.